Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract

• Status: Unknown status
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Carvedilol is known to be effective in reducing ventricular arrhythmias and mortality in patients with heart failure. It is suggested that one of the mechanisms is its ability to block store overload-induced Calcium release which activates spontaneous calcium release by Ryanodine receptors. Ventricular outflow tract tachyarrhythmia is known to be associated with calcium overload due to activation of Ryanodine receptors. The aim of this study is to evaluate the efficacy of Carvedilol on premature ventricular complex(PVC)/ventricular tachycardia(VT) originating from outflow tract.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Keimyung University Dongsan Medical Center
• Collaborator: Chong Kun Dang Pharmaceutical Corp.
• Treatments: Carvedilol; Flecainide

Criteria

Inclusion Criteria:

• Patients with ventricular premature complexes/ventricular tachycardias originating from ventricular outflow tract confirmed on the 12-lead surface ECG

• Patients with PVC burden of 5% or more in 24-hour Holter monitoring

• Patients with normal left ventricular function

• left ventricular ejection fraction ≥50%

• Patients without structural heart disease

Exclusion Criteria:

• Pregnant, trying to become pregnant or breast feeding

• History of bronchial asthma

• History of coronary arterial disease